CA2045231A1 — Cell membrane glycoprotein correlated with resistance to platinum-containing antineoplastic agents
Assigned to Ontario Cancer Institute · Expires 1992-01-20 · 34y expired
What this patent protects
Abstract of the Disclosure A novel plasma membrane glycoprotein having an approximate molecular weight of 200 kDa has been isolated. The glycoprotein is correlated with CDDP-resistance in murine thymic lymphoma cell sublines from which it was isolated. The glycoprotein, designat…
USPTO Abstract
Abstract of the Disclosure A novel plasma membrane glycoprotein having an approximate molecular weight of 200 kDa has been isolated. The glycoprotein is correlated with CDDP-resistance in murine thymic lymphoma cell sublines from which it was isolated. The glycoprotein, designated CPR-200, appears to be correlated with resistance to the platinum family of anti-neoplastic drugs across species.
Drugs covered by this patent
- Vizimpro (Dacomitinib) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.